The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, is calling upon the industry to improve collaborative efforts to use patient data to its full effect. In a series of keynote speeches delivered at The Pistoia Alliance’s annual member conference in London, speakers from Amgen, Accenture and AstraZeneca, discussed the need to more closely connect outcomes data with the R&D process – to help pharmaceutical companies focus their research efforts and deliver real benefits to patients. Building machine learning and deep learning systems, and incorporating data from therapeutic interventions or diagnostics into R&D is technologically challenging, and would benefit significantly from industry-wide pre-competitive collaboration...
Janssen
See the following -
Johnson & Johnson Announces Clinical Trial Data Sharing Agreement With Yale School of Medicine
Johnson & Johnson today announced that its subsidiary, Janssen Research and Development, LLC, has entered into a novel agreement with Yale School of Medicine's Open Data Access (YODA) Project that will extend its commitment to sharing clinical trials data to enhance public health and advance science and medicine.
- Login to post comments
tranSMART Foundation Announces Version 16.2 - A Collaborative Effort of the tranSMART Community
The tranSMART Foundation, a non-profit organization providing a global, open-source, open-data knowledge management platform for scientists to share pre-competitive translational research data, today announced the newest release of its tranSMART platform, version 16.2. This version includes significant contributions from numerous members of the tranSMART community and provides users with more advanced functionality to enhance their translational research studies...
- Login to post comments
“Open Source” Drug Discovery - €196M Program Launched
Major pharma firms have joined together in a consortium with academics and SMEs that will invest €196 million in a new project to give a boost to ‘open-source’ drug discovery in the EU. Read More »
- Login to post comments